Carregant...
Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
With the expansive use of immune checkpoint inhibitors, the frequency of immune‐related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti‐programmed death‐ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcinoma thera...
Guardat en:
| Publicat a: | J Diabetes Investig |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717815/ https://ncbi.nlm.nih.gov/pubmed/30738003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13022 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|